Ongoing Clinical Studies

Mindstrong Health is participating in several trials selected to test the value of digital phenotyping in clinical populations.

Depression

  • Goal

    Define digital biomarkers and digital phenotypes correlated with cognition, brain imaging, and mood in patients with depression and obesity undergoing psychosocial treatments.

  • n = 200

  • Completion

    Phase 1 (n = 100) 2017 Q2, Completion of Phase 2 (n = 100) 2019

  • Partner

    Stanford University (funded by NIH)

  • Goal

    Define the digital biomarkers and digital phenotypes that predict recovery and relapse in depressed patients treated with ketamine.

  • n = 30

  • Completion

    2018 Q1

  • Partner

    Kadima Clinic (funded by Mindstrong). See clinicaltrials.gov for more information.

  • Goal

    Define the digital biomarkers and digital phenotypes that predict stress-induced depression in medical interns.

  • n = 550

  • Completion

    2018 Q3

  • Partner

    University of Michigan (funded by NIH)

  • Goal

    Define the digital biomarkers and digital phenotypes that can serve as an outcome measure in a randomized clinical trial of a new antidepressant (Phase 2a).

  • n = 100

  • Completion

    2018 Q4

  • Partner

    Blackthorn Therapeutics (funded by Blackthorn Therapeutics)

  • Goal

    Use smartphone digital biomarkers and digital phenotypes to measure and potentially predict relapse in major depressive disorder.

  • n = 200

  • Completion

    2020 Q1

  • Partner

    King’s College London, via the RADAR-CNS study.*

*The RADAR-CNS study has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115902. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

Severe Mental Illness

  • Goal

     Identify digital biomarkers and digital phenotypes that predict changes seen on serial MRI in schizophrenia.

  • n = 30

  • Completion

    2018 Q2

  • Partner

    Yale University

  • Goal

    Define digital biomarkers and digital phenotypes related to clinical outcomes in schizophrenia, bipolar and major depressive disorder.

  • n = 3000

  • Completion

    2019 Q1

  • Partner

    Zhejiang University, China

  • Goal

    Define digital biomarkers and digital phenotypes to identify young adults at risk for psychosis.

  • n = 300

  • Completion

    2020 Q1

  • Partner

    King’s College London

PTSD

  • Goal

    Define the digital biomarkers and digital phenotypes that predict onset of PTSD following a traumatic event.

  • n = 5000

  • Completion

    2022

  • Partner

    University of North Carolina (funded by NIMH)